ID
45646
Beschreibung
Principal Investigator: Neal Freedman, PhD, MPH, National Cancer Institute, Rockville, MD, USA MeSH: Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001286 The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was completed in 2006. However, participants have been under follow-up for cancer incidence and mortality since that time. In addition, PLCO included a large biological sample biorepository which has served as a unique resource for cancer research, particularly for etiologic and early-marker studies. As part of these efforts, PLCO has been used for a large number of genome-wide association and exome sequencing studies for different types of cancer.
Link
Stichworte
Versionen (1)
- 20.03.23 20.03.23 - Simon Heim
Rechteinhaber
Neal Freedman, PhD, MPH, National Cancer Institute, Rockville, MD, USA
Hochgeladen am
20. März 2023
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs001286 The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)
Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sample ID sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Sample ID, histological type of sample, body site where sample was obtained, analyte type, tumor status of sample, and array platform of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
Ähnliche Modelle
Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sample ID sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Subject ID and sex of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
- Sample ID, histological type of sample, body site where sample was obtained, analyte type, tumor status of sample, and array platform of participants with or without prostate, lung, colon, and ovary cancer and involved in the "The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)" project.
C2348585 (UMLS CUI [1,2])